The Advantage of Plant-based Expression Solutions Around the Globe

iBio offers development and manufacturing services for biologic drug substances and drug products, built around our proprietary plant-based platform technology. Client support is offered from early development through fill and finish for research-grade, pre-clinical, clinical and commercial material, including extensive scale-up and analytical and regulatory assistance. Customers have the option of adopting iBio’s technology in their own facilities, which iBio will help design to ensure optimal production under cGMP-compliant conditions.


iBio Announces First Agreement for Fill-Finish Services

NEW YORK, June 19, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced the activation of its new cGMP sterile fill-finish services operation via the signing of a supply agreement with a clinical-stage biopharmaceutical company developing breakthrough gene and cell therapies (the “Customer”).


Animal Health Investment Forum

August 26-27, 2019
Kansas City Convention Center
Kansas City, MO


Why FastPharming ?

FastPharming overcomes the limitations of other expression systems:

  • No time wasted finding high-producing clones and establishing master cell banks
  • Simple, easy scale-up
  • Sustainable manufacturing – Less plastic waste compared to mammalian single-use systems
  • Accessible, flexible glycosylation controls
  • Safer – reduced risk of viral contamination
  • Lower facility capital expenditure
  • Increases speed-to-market
Learn More

Increased Speed-to-Market

iBio CDMO Services

Process Development

FastPharming optimizes gene-expression, glycosylation, and purification parameters to deliver a robust process for your APIs.

cGMP Manufacturing

The FastPharming system transfects at large-scale to easily and reliably deliver biologics in clinical trial or commercial quantities.

Aseptic Fill/Finish

In-line labelling allows serialization of vials and bottles for greater quality assurance of mAbs, viral vectors, and other biologics.


Experienced analytical staff provides method development and validation support with expertise in protein characterization using mass spectrometry.

Quality & Regulatory

Quality systems have been carefully constructed to meet cGMP requirements and iBio can provide regulatory guidance given the team’s experience with therapeutic development.

Factory Solutions

When the time is right, iBio facilitates insourcing by designing and building your own environmentally sustainable FastPharming facilities.

Technology Applications

The FastPharming platform produces a variety of recombinant products including:

  • Biobetter and biosimilar antibodies
  • Antigens for subunit vaccine design
  • Virus-like particles (VLP)
  • Lysosomal enzymes
  • Blood factors and cytokines
  • Scaffolds, maturogens and materials for 3D Bioprinting and biofabrication

Contact Us

Interested in applying the power of FastPharming to your project?

iBio offers the CDMO capabilities needed to develop and deliver biologics to market - process development, scale-up, cGMP manufacturing, bioanalytical product characterization, aseptic fill/finish, and quality and regulatory support.

Send us a Message